NCT06606106

A Study of LY3537031 in Overweight, Obese, and Healthy Participants

A Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of LY3537031 in Overweight and Obese Participants and Healthy Volunteers

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 302 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 22 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 49 weeks excluding a screening period.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	LY3537031	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2024-09-05
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2024-09-20
• Last updated: 2026-01-20

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study